IMVT
Immunovant·NASDAQ
--
--(--)
--
--(--)
IMVT fundamentals
Immunovant (IMVT) released its earnings on Feb 6, 2026: revenue was 0 (YoY 0.00%), met estimates; EPS was -0.5378 (YoY +29.24%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.5378
+29.24%
Report date
Feb 6, 2026
IMVT Earnings Call Summary for Q3,2026
- Phase II Breakthrough in CS: Brepocitinib demonstrated 21.6-point CSAMI improvement (p < 0.001), with 100% high-dose patients achieving ≥10-point improvement.
- 2026 Catalysts: Phase III CS trial, Moderna trial, and mosli data in PH-ILD expected to drive 2026 growth.
- Financial Strength: $4.5B cash to support pipeline expansion and strategic initiatives.
EPS
Revenue
Revenue & Expenses
Key Indicators
Immunovant (IMVT) key financial stats and ratios, covering profitability, financial health, and leverage.
Immunovant (IMVT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Immunovant (IMVT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Immunovant (IMVT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Immunovant (IMVT) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Immunovant (IMVT) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What is Immunovant's gross profit margin?What factors drove the changes in Immunovant's revenue and profit?What is Immunovant's latest dividend and current dividend yield?What is the market's earnings forecast for Immunovant next quarter?What does Immunovant do and what are its main business segments?What is the revenue and EPS growth rate for Immunovant year over year?What guidance did Immunovant's management provide for the next earnings period?What were the key takeaways from Immunovant's earnings call?
